ACROBiosystems社 Next-generation influenza vaccines: Unleash the potential

Next-generation influenza vaccines: Unleash the potential

Current influenza vaccines struggle to keep pace with the virus’s rapid evolution. This mismatch leads to low effectiveness and seasonal outbreaks.

Universal influenza vaccine hold the key to key-round protection. Our high-quality, consistent antigens & antibodies empower your research towards this goal!

Explore key reagents aligned with WHO recommendations!

WHO recommendations strains	Hemagglutinin (HA)	Neuraminidase (NA)
A/Victoria/4897/2022 (H1N1)pdm09-like virus	(Cat. No. HA1-V52H8)	(Cat. No. NEE-V524c)
A/Wisconsin/67/2022 (H1N1)pdm09-like virus	(Cat. No. HA1-V52H7)	(Cat. No. NEE-V524m)
B/Austria/1359417/2021 (B/Victoria lineage)	(Cat. No. HAE-V52H3)	(Cat. No. NEE-V5245)
B/Phuket/3073/2013 (B/Yamagata lineage)	(Cat. No. HAE-V52H4)	(Cat. No. NEE-V5246)

Click for More Reagents for Flu Research

Flu Antigen Binding Activity (ELISA)

Immobilized Influenza A [Victoria/4897/2022] Hemagglutinin (HA) Protein, His Tag (Cat. No. HA1-V52H8) at 1 µg/mL (100 µL/well) can bind Human Anti-HA (H1N1) antibody3E1 with a linear range of 1-31.25 ng/mL (QC tested).

Download the Protocol

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。